Elisabeth Rosenthal

Visit kff.org to read Elisabeth's bio.

erosenthal@kff.org
@RosenthalHealth

La crisis de deuda que los estadounidenses enfermos no pueden evitar

Poca atención pública se ha centrado en lo que es, al menos estadísticamente, una crisis de deuda más grande: se estima que 100 millones de personas, o el 41% de todos los adultos del país, tienen deudas de atención médica, en comparación con 42 millones con deuda estudiantil.

Will the US Overcome Its Covid Complacency Even as the Threat Returns?

One million Americans have died from covid-19 — far more per capita than in any other developed country. A new variant is doubling case rates in some states, and more than 300 people are dying a day. But our nation’s pandemic response has become mild-mannered and performative, backed by neither money, urgency, nor enforcement.

Is My Drug Copay Coupon a Form of Charity — Or a Bribe?

Drug copayment assistance is a form of profitable charity — and, yes, that’s an oxymoron. Amid skyrocketing drug prices, it’s understandable that patients desperately need help affording medicine, especially when their health is on the line. But these programs create a mirage that perpetuates our health care system’s reckless spending.

The End of the Covid Emergency Could Mean a Huge Loss of Health Insurance

It is a perilous time to throw low- and middle-income Americans off the insurance cliff: A new omicron subvariant is spreading, and a program that provided coronavirus testing and covid-19 treatment at no cost to the uninsured has expired.

Polio, Chickenpox, Measles, Now Covid. It’s Time to Consult History on School Vaccine Mandates

As some states adopt covid vaccine requirements, not everyone agrees mandates for children are the way forward. Taking a page from history: We have two paths to putting the pandemic behind us: a quicker, more certain one of mandatory vaccination or a stuttering, drawn-out, likely more deadly affair.

Public Opinion Is Unified on Lowering Drug Prices. Why Are Leaders Settling for Less?

Politicians and many health experts have done their best to see the glass half-full in the plan put forward by congressional Democrats and the president. But it’s “a far cry” from what other nations do to rein in drug prices, and polls show most voters demand more protection.